American Century Companies Inc. Has $2.18 Million Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

American Century Companies Inc. boosted its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 304.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 113,562 shares of the company's stock after buying an additional 85,512 shares during the period. American Century Companies Inc. owned approximately 0.14% of Viridian Therapeutics worth $2,177,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quantbot Technologies LP bought a new position in Viridian Therapeutics during the fourth quarter worth about $164,000. DCF Advisers LLC boosted its stake in Viridian Therapeutics by 105.2% during the 4th quarter. DCF Advisers LLC now owns 29,750 shares of the company's stock worth $570,000 after acquiring an additional 15,250 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in Viridian Therapeutics by 21.6% during the fourth quarter. Teacher Retirement System of Texas now owns 17,015 shares of the company's stock valued at $326,000 after purchasing an additional 3,028 shares during the period. Swiss National Bank grew its holdings in Viridian Therapeutics by 4.2% during the fourth quarter. Swiss National Bank now owns 112,600 shares of the company's stock valued at $2,159,000 after purchasing an additional 4,500 shares during the period. Finally, AlphaQuest LLC increased its stake in Viridian Therapeutics by 119.0% in the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock valued at $54,000 after purchasing an additional 1,519 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on VRDN shares. Royal Bank of Canada lifted their price target on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 17th. Needham & Company LLC reiterated a "buy" rating and set a $38.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Wells Fargo & Company restated an "equal weight" rating and issued a $27.00 price target (down from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Finally, HC Wainwright reiterated a "buy" rating and set a $34.00 price objective on shares of Viridian Therapeutics in a report on Monday, December 16th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Viridian Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.70.

Viridian Therapeutics Stock Up 5.3 %

NASDAQ VRDN traded up $0.61 during trading on Friday, hitting $12.02. The stock had a trading volume of 1,208,187 shares, compared to its average volume of 1,194,149. The company has a market capitalization of $979.45 million, a PE ratio of -2.79 and a beta of 0.81. Viridian Therapeutics, Inc. has a 12 month low of $9.90 and a 12 month high of $27.20. The company's 50-day moving average price is $15.08 and its two-hundred day moving average price is $18.91. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, beating analysts' consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The business had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.05 million. As a group, sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.